Original Resear	Volume-8 Issue-1 January-2018 PRINT ISSN - 2249-555X Anesthesiology
Dr. Sameer V	
Kulkarni	
Dr. Harshad	*Comments that there
Dongare*	*Corresponding Author
necessar cause of VAP. To prevent this asp needs to be studied. Objective: TO determine wheth Materials & Methods: The pre-	bund: Ventilator associated pneumonia (VAP) is an important health issue in any Intensive Care Unit (ICU). It is ry to reduce overall incidence of VAP in ICU patients. Aspiration of tracheal secretions into lungs is the main piration, different strategies are employed. Out of which, intermittent subglottic secretion drainage is newer one & the subglottic secretion device (SSD) reduces incidence of VAP.
	nts, 50 were having SSD ETT & 50 patients had ETT without SSD. Out of these 100 patients, 18 patients had

Results: Out of total 100 patients, 50 were having SSD E11 & 50 patients had E11 without SSD. Out of these 100 patients, 18 patients had microbiologically confirmed VAP. Out of these 18 patients 7 patients were from SSD tube study group & 11 patients from control group.

Conclusion: Use of SSD ETT can reduce incidence of early VAP. Also it act in unison with other methods to prevent VAP but more studies are required to demonstrate its effect on length of ICU stay and duration of mechanical ventilation.

KEYWORDS : Subglottic suction drainage, Ventilator associated pneumonia

Introduction:

VAP (Ventilator Associated Pneumonia) is an important health issue in ICU, as it carries significant morbidity, increase in duration of mechanical ventilation, hospital stay & overall mortality.

VAP is defined as pneumonia that develops 48 hours after mechanical ventilation is initiated & characterized by

- 1) Presence of new/progressive infiltrate,
- 2) Signs of SIRS like >10000 TLC <3000, fever,
- 3) Changes in Endotracheal Tube secretions color & consistency
- 4) Detection of causative agent

Confirmation of pneumonia by finding causative microbiological agent in all patients ET samples may not be possible in all patients. One may require protected telescopic catheter sample or BAL (bronchoal veolar lavage) fluid.

VAP is also divided into early onset VAP (<5days) & late onset VAP (>5 days).

Materials & Methods:

This study was conducted in surgical ICU of teaching hospital in western Maharashtra. Inclusion criteria is 100 elective and emergency patients who came to SICU intubated above age of 18 years who required mechanical ventilation for more than 5 days.

Exclusion criteria

1) Patients with tracheostomy

- 2) Patients with mechanical ventilation requirement less than 48 hours
- 3) Patients intubated after cardiac arrest or received CPR.

Patients requiring mechanical ventilation were intubated using either portex ETT or portex SSD (subglottic suction device) ETT. In the SSD group, subglottic secretions were suctioned manually with a 10 ml syringe, every 2 hourly. Oropharyngeal & intratracheal close suctioning of secretions done in both groups every 4 hourly & also whenever required. Total volume of secretions suctioned were noted.

VAP is defined as pneumonia that develops 48 hours after mechanical ventilation is initiated & characterized by

- 1) Presence of new/progressive infiltrate,
- 2) Signs of SIRS like >10000 TLC <3000, fever,
- 3) Changes in Endotracheal Tube secretions color & consistency

4) Detection of causative agent

Confirmation of pneumonia by finding causative microbiological agent in all patients ET samples may not be possible in all patients. One may require protected telescopic catheter sample or BAL (bronchoal veolar lavage) fluid. VAP is also divided into early onset VAP (<5 days) & late onset VAP (>5 days).

RESULTS-: Demographic data Table 1

Parameter	Group SSD	Group C	P Value
Age (yrs)	56.35+/-(14.5)	58.41+/-(21.6)	0.576
Sex(M/F)	26/24	23/27	0.689
Type of surgery			
Elective	38	41	0.6234
Emergency	12	9	
Specialty wise			
Surgery	29(58%)	24(48%)	0.423
Neurosurgery	4(8%)	3(6%)	0.695
Orthopedics	11(11%)	18(%)	0.186
Maxillofacial	2(4%)	2(4%)	1.00
OBGY	4(8%)	3(6%)	0.6951
Previous co- morbidities			
IHD	16(32%)	13(26%)	0.6594
COPD	11(22%)	7(14%)	0.434
DM	14(28%)	19(38%)	0.394
Malignancy	6(12%)	8(16%)	0.773
CRF	2(4%)	1(2%)	0.557
No Co-morbidities	14(28%)	12(24%)	0.819

Mean +/- (standard deviation)

IHD- ischemic heart disease, COPD- Chronic obstructive pulmonary disease, DM-diabetes mellitus, CRF-chronic renal failure

 Table 2 VAP rate, Duration of mechanical ventilation, and survival outcome

	Group SSD	Group C	P Value
Early VAP			
No. of patients with early VAP (%)	2(4%)	5(10%)	0.4331
No. of patients with early VAP (%)	2(4%)	5(10%)	0.4331

26 INDIAN JOURNAL OF APPLIED RESEARCH

Late VAP			
Late VAP rate [*]	14.7/1000	16.9/1000	
No of patients with Late VAP (%)	5(10%)	6(12%)	0.7501
Average duration of MV (days)	6.8+/-(2.8)	7.1+/-(3.9)	0.6596
No. of deaths (%)	2(4%)	3(6%)	0.646

*Cases/1000 ventilator days

MV-mechanical ventilation

Discussion-:

Ventilator Associated Pneumonia (VAP) results from leakage of oropharyngeal secretions around the endotracheal tube cuff which enters the normally sterile lower respiratory tract and lung parenchyma resulting in invasion of bacteria.¹⁻⁴Different methods have been used to prevent VAP but still 9-27% of patients who are mechanically ventilated in ICU develop VAP and it remains an important cause of morbidity and mortality

There are two methods to reduce incidence of VAP, one which reduces the time at risk of VAP such as early extubation & reducing duration of mechanical ventilation and secondly interventions which reduce the volume of secretions aspirated e.g. use of Subglottic Suction endotracheal tubes and semi recumbent position⁷. Third intervention which reduces the inoculums of bacteria in secretions are chlorhexidine mouthwash & selective digestive decontamination (SDD)⁸.

Semirecumbency is always not possible in postoperative patients e.g. spine surgeries & cannot be implemented continuously so subglottic suction devices are advantageous in such circumstances to prevent VAP⁹. SDD is expensive & there is concern of developing microbial resistance. Similarly chlorhexidine mouthwash does not completely sterilize the upper airway, so cannot prevent VAP completely

So decreasing the amount of secretions aspirated remains the important method for VPA prevention, which can be achieved by using SSD^{11, 12, 13}Also Muscendere & Rewa et al in there meta-analysis suggested that SSD and chlorhexidine mouthwash are complementary to each other in VAP prevention rather than using only one method either¹⁴A recent study by Kollef et al¹⁵ found 36% reduction in incidence rate of VAP by using silver coated endotracheal tubes but doesn't found any effect on reduction of duration of mechanical ventilation and length of ICU stay.

Specially designed endotracheal tube with sub-glottic secretion drainage (SSD) was first described in 1992¹⁶ to prevent VAP. It has separate dorsal lumen that opens just above the endotracheal tube cuff. A meta-analysis of studies using SSD to prevent VAP has shown SSD is useful in preventing Early VAP¹⁷ but whether it is useful in preventing late VAP is still controversial^{18,19}. In our study intermittent SSD resulted in significant reduction in overall incidence of Early VAP rate i.e. 5.8 vs. 14/1000 ventilator days with p value of 0.4331 which is significant, but we didn't found significant difference in incidence of late VAP Rate i.e.14.7 vs.16.9/1000 ventilator days with p value of 0.7501 which is not significant.

There is variation in volume of secretions suctioned & according to one study the volume ranges between 0.3-15 ml²⁰. These variations are because of variable amount of secretions present above the cuff, secretion viscosity, suction pressure and related to difficulties in maintaining patency of subglottic suction line and cuff inflation pressure²¹.Manual, Automatic, intermittent or continuous suction methods are proposed in litarature²² but most effective method is still unclear.

Not only there is marked decrease in the incidence of microbiolog ically confirmed VAP with the use of SSD in our study but also Duration of mechanical ventilation and length of ICU stay. Mortality benefits are not significant. Meta-analysis by Dezfullian et al showed significant reduction in duration of mechanical ventilation & ICU stay in patients with SSD¹⁷ According to systemic review & meta-analysis by Muscendere & Rewa et al¹⁴ there is more than 50% reduction in incidence of VAP with use of SSD, but its strength of association with reduction in duration of mechanical ventilation and length of ICU stay is weak as various surgical factors and co-morbidities play crucial role in these outcomes

ETT with SSD are not widely utilized²⁴ because of cost & inability to judge which patients will require prolonged mechanical ventilation & are at risk of VAP. According to Shere et al²⁶ & Muscendere and Rewa et al using SSD is cost effective than treating VAP with costly antibiotics and prolonging duration of icu stay and mechanical ventilation. Regarding second issue all patients who are intubated in ER, ICU, and Ward should have SSD ETT. According to Bouza et al² all operative patients who are expected to require post operative mechanical ventilation should have SSD ETT but whether to change the ETT is not clear

There are some drawbacks of using SSD as secretion properties & malposition of suction port which may lead to decreased suction²⁸ Larente et al³⁰demonstrated that new cuff design can reduce micro aspiration with SSD with polyurethane cuff. Complications like postextubation stridor and re-intubation are found in only 3 out of 13 studies which used SSD in meta-analysis by Muscendere & Rewa et al¹⁴ also it is only reported in animal models³¹. Some case reports³² which described tracheal injuries after prolonged use of SSD are present but no studies.

Described airway injuries with use of SSD³³. In our study there were no complications related to airway as well as no difference in incidence of post-extubation dyspnoea, or re intubation rate in two groups.

Conclusion-:

Use of SSD ETT can reduce incidence of early VAP. It is cheap, easily available harmless option. It can be implemented in all patients who might require prolonged mechanical ventilation. Also it act in unison with other methods to prevent VAP but more studies are required to demonstrate its effect on length of ICU stay and duration of mechanical ventilation as co-morbidities and other confounding factors may play a significant role in these outcomes.

REFERENCES

- American Thoracic Society, Infectious Diseases Society of America. Guidelines for management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
- Okkonem M, Aaroma U. Leakage of fluid around low pressure tracheal tube cuff. 2. Anesthesia 1997;52:567-69.
- Petring OU, Adelhoj B, Jenesan BN, Pederson NO, Lomholt N, Prevention of silent aspiration due to leaks around endotracheal tubes. Anesth Analg 1986;65:777-780. 3. 4
- Young PJ, Rollinson M, Downward G, Henderson S. Leakage of fluid past the endotracheal tube cuff in a benchtop model.Br J Anesth 1997;78:557-562. Chaster J, Fangon JY. Ventilator associated pneumonia. Am J Respir Crit Care Med 5.
- 2002:165:867-903 Klompas M. Does this patient has ventilator associated pneumonia JAMA
- 6 2007:297:1583-1593.
- Drakulovic MB, Torres A, Baeur TT, et al: Supine body position as a risk factor for 7. nosocomial pneumonia in mechanically ventilated patients: A randomized trial. Lancet 1999; 354:1851-1858.
- Libareti A, D'Amico R, Peifferi S, et al. Antibiotic prophylaxis to reduce respiratory tract infections and mortalitynin adults receiving intensive care. Update of Cochrane Database System Rev 2009; Cd000022
- Van Nieuwenhoven CA, Vandenbroucke-Grauls C, Van Tiel FH, et al: Feasibility and effects of semi recumbent position to prevent ventilator associated pneumonia: A randomized study.Crit Care Med 2006; 34:396-402. Chan EY, Ruset A, Meade M, et al: oral decontamination for prevention of pneumonia in 9
- 10. mechanically ventilated adults: Systemic Review and analysis. BMJ 2007; 10:1136.
- Lorebet L, Leucona M, Jimenez A, et al: Influence of endoracheal tube with polyurethane cuff and subglottic suction drainage on pneumonia, Am J Respir Crit Care 11 Med 2007:176:1079-1083.
- Bouza E, Perez MJ, Mounoz P, et al: Continuous aspiration of subglottic secretions in the 12. prevention of ventilator associated pneumonia in the postoperative period of major heart surgery. Chest 2008;134:938-946.
- Yang CS, Qiu HB, Zhu YP, et al: Effect of Continuous aspiration of subglottic secretions in the prevention of ventilator associated pneumonia in mechanically ventilated patients: A prospective randomized controlled clinical trial. Chung-Hua Nei Ko Tsa Chich 2008;20:338-340.
- Muscendere J, Rewa O, et al: Subglottic suction drainage for the prevention of ventilator 14. associated pneumonia: a systemic review and meta-analysis; Crit Care Med 2011;39:8:1985-1991.
- Kollef MH, Afessa B, Anzueto A, et al:and the NASCENT Investigation group. Silver coated endotracheal tubes and incidence of ventilator associated pneumonia: The NASCENT randomized trial. JAMA 2008;300:805-813.
- Mahul P, Auboyer C, Jospe R et al; prevention of nosocomial pneumonia in intubated patients: respective role of subglottic secretions drainage and stress ulcer prophylaxis. 16. Intensive Care Med 1992;18:20-25. Dezfulian C, Shojania K, Collard HR, Kim HM, Matthay MA, Saint S. subglottic
- 17 secretion drainage for preventing ventilator associated Pneumonia: A meta-analysis, Am IMed 2005:118:11-18
- Coffin SE, Klompas M, Classen D, Arias K, Podogorny K, Anderson DJ, Burstin H, Calfee DP. Strategies to prevent ventilator associated pneumonia in acute care hospitals.Infect Control Hosp Epidemiol 2008;29:s31-s40. 18.
- Cook D, Ricard JD, Revee B, Randal J, Wigg M, Bochard L, Dreyfuss D.ventilator 19 circuits and secretion management strategies: a Franco-Canadian survey. Crit Care Med 2000;28:3547-3554.
- O'neil PV, Munro CI, Grap MJ, Rausch SM. Subglottic secretion viscocity and evacuation efficacy. Biol Res Nurs2007;8:202-209. 20
- Depew CL, McCarthy MS. Subglottic secretion drainage: A literature review.AACN Adv Crit Care 2007;19:366-379. 21.
- Samuels K, van der Hoven H, Wears-Pothoff I. A randomized controlled clinical trial of 22 intermitant subglottic siction darianage in patients receiving mechanical ventilation.

27

Chest 2002;121:858-862.

- Chest 2002;121:858-862. Krein SI, Kowalski CP, Damscroder L, et al: Preventing ventilator associated pneumonia in the united states: A multicenter mixed methods study. Infect Control, Hosp epidemiol 2008;29:933-940 Muscendere JG, Day A, Heyland DK: Mortality, attributable mortality,and time to 23.
- 24.
- Indectidate vis, as and points for clinical trial of ventilator associated pneumonia and hospital acquired pneumonia. Clin Infect Dis2010;51:s120-s125. Shorr AF, O'Malley PG: Continuous subglottic suctioning for the prevention of ventilator associated pneumonia: Potential economic implications. Chest 2001;110:272:225 25.
- Ventiator associated pneumonia: Potential economic implications. Crest 2001;119:228-235. Dragoumanis CK, Verzakis GI, Papaioannou Ve et al: Investigating the failure to aspirate subglottic secretions with the Evac endotracheal tube. Anaesth Analg 2007;105:1083-1085. 26.
- O'neil PV, Munro CL, Grap MJ, et al: Subglottic secretions viscocity and evacuation 27. 28.
- 29.
- O heir PV, Multor CL, Grap MJ, et al. Subjoint secretions viscocity and evacuation efficacy. Biol Resrnursing 2007;8:220.
 Berra L, De Marchi L, Panigada M, et al. Evaluation of continuous aspiration of subglottic secretion in an in vivo study. Crit Care Med 2004;32:2071–2078.
 Harvey R, Miller P, Lee J, et al. Potential mucosal injury related to continuous aspiration of subglottic secretion device. Anesthesiology 2007;107:666–669.
 Value II. Maritering intergent for ensure in the subglottic secretion for the subglottic secretion.
- Valles J: Monitoring intracuff pressure in subglottic aspiration. Crit care Med 2005;33:1649-1470. 30.